| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.16 | 0.008 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.16 | 0.008 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.008 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.16 | 0.008 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.01 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.096 | 0.01 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.01 |